期刊
EMERGING MICROBES & INFECTIONS
卷 8, 期 1, 页码 516-530出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2019.1597644
关键词
Coronavirus; MERS; antibodies; spike protein
资金
- IMI-ZAPI (Zoonotic Anticipation and Preparedness Initiative (ZAPI) project)
- IMI-ZAPI (Innovative Medicines Initiative (IMI)) [115760]
- IMI
- European Commission
- Ministry of Science and Innovation of Spain [BIO2016-75549-R]
- NIH [2PO1AIO6O699]
- Center for Scientific Review, China Scholarship Council
The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively, these antibodies offer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting different spike protein epitopes and functions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据